Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (23)
Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi & Nupur Greene. (2023) Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. ClinicoEconomics and Outcomes Research 15, pages 361-373.
Read now
Read now
Enrique Alvarez, Kavita V. Nair, Hiangkiat Tan, Kapil Rathi, Nicole B. Gabler, Eric M. Maiese, Chinmay Deshpande & Qiujun Shao. (2023) Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. Journal of Medical Economics 26:1, pages 494-502.
Read now
Read now
Nupur Greene, Keiko Higuchi, Katalin Bognar, Eunice Chang & Michael S Broder. (2022) Medication Adherence and Healthcare Utilization in Relapsing-Remitting Multiple Sclerosis Patients Using Teriflunomide. ClinicoEconomics and Outcomes Research 14, pages 755-761.
Read now
Read now
Samuel F Hunter, Jas Bindra, Ishveen Chopra, John Niewoehner, Mary P Panaccio & George J Wan. (2021) Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis. ClinicoEconomics and Outcomes Research 13, pages 883-892.
Read now
Read now
Leorah Freeman, Arianna Kee, Marc Tian & Rina Mehta. (2021) Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients. ClinicoEconomics and Outcomes Research 13, pages 65-75.
Read now
Read now
Carrie M. Hersh, Richard A. Brook, Ian A. Beren, Nicholas J. Rohrbacker, Lori Lebson, Christian Henke & Amy L. Phillips. (2021) The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis. Journal of Medical Economics 24:1, pages 479-486.
Read now
Read now
Regina Berkovich, Edward Fox, Annette Okai, Yao Ding, Magdaliz Gorritz, Lauren Bartolome, Rolin L. Wade, Wendy Su, Kristen M. Johnson & Patricia Russo. (2021) Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database. Journal of Medical Economics 24:1, pages 46-53.
Read now
Read now
Jacqueline Nicholas, Rachel Halpern, Marina Ziehn, Jesse Peterson-Brandt, Michael Leszko & Chinmay Deshpande. (2020) Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States. Journal of Medical Economics 23:8, pages 885-893.
Read now
Read now
Benjamin Greenberg, Steven Hall, Michael Grabner, Sanjeev Balu, Xian Zhang & Daniel Kantor. (2020) Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate. Current Medical Research and Opinion 36:7, pages 1167-1175.
Read now
Read now
Maria Cecilia Vieira, Devon Conway, Gina Mavrikis Cox, Miranda Peeples, Arielle G. Bensimon, Monica Macheca & Vivian Herrera. (2020) Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study. Current Medical Research and Opinion 36:2, pages 261-270.
Read now
Read now
Matthew Putnam, Mollie Vanderkarr, Piyush Nandwani, Chantal E. Holy & Abhishek S. Chitnis. (2019) Surgical treatment, complications, and reimbursement among patients with clavicle fracture and acromioclavicular dislocations: a US retrospective claims database analysis. Journal of Medical Economics 22:9, pages 901-908.
Read now
Read now
Chao Chen, Ning Wu & Crystal Watson. (2018) Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. ClinicoEconomics and Outcomes Research 10, pages 723-730.
Read now
Read now
Mitzi J. Williams, Kristen Johnson, Helen M. Trenz, Stephanie Korrer, Rachel Halpern, Yujin Park & Vivian Herrera. (2018) Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate. Current Medical Research and Opinion 34:1, pages 107-115.
Read now
Read now
Jack Burks, Thomas S Marshall & Xiaolan Ye. (2017) Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. ClinicoEconomics and Outcomes Research 9, pages 251-260.
Read now
Read now
Frank A. Corvino, David Oliveri & Amy L. Phillips. (2017) The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records. Current Medical Research and Opinion 33:6, pages 1127-1132.
Read now
Read now
Xuehua Ke, Prakash Navaratnam, Rahul Sasane, Debra F. Eisenberg Lawrence, Howard S. Friedman, Bernard B. Tulsi & Timothy Vollmer. (2016) Determinants of high cost in multiple sclerosis patients: a claims and chart review study. Current Medical Research and Opinion 32:9, pages 1589-1597.
Read now
Read now
R Brett McQueen, Kavita V Nair, Timothy L Vollmer & Jonathan D Campbell. (2015) Incorporating real-world clinical practice in multiple sclerosis economic evaluations. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 869-872.
Read now
Read now
Dietrich Rothenbacher, Gorana Capkun, Hatice Uenal, Hayrettin Tumani, Yvonne Geissbühler & Hugh Tilson. (2015) New opportunities of real-world data from clinical routine settings in life-cycle management of drugs: example of an integrative approach in multiple sclerosis. Current Medical Research and Opinion 31:5, pages 953-965.
Read now
Read now
Gorana Capkun, Raquel Lahoz, Elisabetta Verdun, Xue Song, Weston Chen, Jonathan R. Korn, Frank Dahlke, Rita Freitas, Kathy Fraeman, Jason Simeone, Barbara H. Johnson & Beth Nordstrom. (2015) Expanding the use of administrative claims databases in conducting clinical real-world evidence studies in multiple sclerosis. Current Medical Research and Opinion 31:5, pages 1029-1039.
Read now
Read now
Niklas Bergvall, Raquel Lahoz, Tracy Reynolds & Jonathan R. Korn. (2014) Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Current Medical Research and Opinion 30:8, pages 1461-1471.
Read now
Read now
Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Allison Petrilla, Swapna U. Karkare, Catherine Balderston McGuiness & Jonathan R. Korn. (2013) Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Current Medical Research and Opinion 29:12, pages 1647-1656.
Read now
Read now
Daniel E. Furst, Ann Clarke, Ancilla W. Fernandes, Tim Bancroft, Kavita Gajria, Warren Greth & Serban R. Iorga. (2013) Medical costs and healthcare resource use in patients with lupus nephritis and neuropsychiatric lupus in an insured population. Journal of Medical Economics 16:4, pages 500-509.
Read now
Read now
M. A. Oleen-Burkey, A. Dor, J. Castelli-Haley & M. J. Lage. (2011) The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. Journal of Medical Economics 14:6, pages 739-747.
Read now
Read now
Articles from other publishers (58)
Yan Song, Yan Wang, Schiffon L. Wong, Danni Yang, Manasvi Sundar & Namita Tundia. (2023) Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States. Multiple Sclerosis and Related Disorders 79, pages 105052.
Crossref
Crossref
Patricia K. Coyle, Magdaliz Gorritz, Rolin L. Wade, Zifan Zhou, Subhan Khalid, Eric M. Maiese, Chinmay Deshpande & Qiujun Samantha Shao. (2023) Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic. Multiple Sclerosis and Related Disorders 78, pages 104881.
Crossref
Crossref
Caroline K. Geiger, Danny Sheinson, Tu My To, David Jones & Nicole G. Bonine. (2023) Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab. Neurology and Therapy 12:5, pages 1709-1728.
Crossref
Crossref
Lilyana Amezcua, Terrie Livingston, Brooke Hayward, Jia Zhou & Mitzi J. Williams. (2023) Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data. Multiple Sclerosis and Related Disorders 77, pages 104866.
Crossref
Crossref
Paul Dillon, Athanasios Siadimas, Spyros Roumpanis, Otto Fajardo, Kocho Fitovski, Nikki Jessop, Louise Whitley & Erwan Muros-Le Rouzic. (2023) Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis. Multiple Sclerosis and Related Disorders 71, pages 104512.
Crossref
Crossref
Lita Araujo, Srikanth Kyatham, Kristen G Bzdek, Keiko Higuchi & Nupur Greene. (2023) Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with multiple sclerosis in the USA. Journal of Comparative Effectiveness Research 12:1.
Crossref
Crossref
Simone Wolf, Abhishek S. Chitnis, Anandan Manoranjith, Mollie Vanderkarr, Javier Quintana Plaza, Laura V. Gador, Chantal E. Holy, Charisse Sparks & Simon M. Lambert. (2022) Surgical treatment, complications, reoperations, and healthcare costs among patients with clavicle fracture in England. BMC Musculoskeletal Disorders 23:1.
Crossref
Crossref
Wen Zhu, Xiaoyu Tang, Rock A. Heyman, Tianxi Cai, Kangho Suh, John D. Seeger & Zongqi Xia. (2022) Patterns of Utilization and Expenditure Across Multiple Sclerosis Disease-Modifying Therapies: A Retrospective Cohort Study Using Claims Data from a Commercially Insured Population in the United States, 2010–2019. Neurology and Therapy 11:3, pages 1147-1165.
Crossref
Crossref
Tjalf Ziemssen, Anna Kurzeja, Bogdan Muresan, Jennifer S Haas, Jessica Alexander & Maurice T Driessen. (2022) Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany. Neurodegenerative Disease Management 12:2, pages 93-107.
Crossref
Crossref
Emilie D. Duchesneau, Alan C. Kinlaw, Michele Jonsson Funk, Virginia Pate & Jennifer L. Lund. (2022) Trends in the use of disease‐modifying therapies among reproductive‐aged women with multiple sclerosis in the United States from 2010 to 2019. Pharmacoepidemiology and Drug Safety 31:4, pages 481-487.
Crossref
Crossref
Leorah Freeman, Arianna Kee, Marc Tian & Rina Mehta. (2021) Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Drugs - Real World Outcomes 8:4, pages 497-508.
Crossref
Crossref
Ruth Ann Marrie, Qier Tan, Okechukwu Ekuma & James J. Marriott. (2021) Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data. Frontiers in Neurology 12.
Crossref
Crossref
Adam BurkhardJoshua ToliverKaren Rascati. (2021) Association between multiple sclerosis disease severity and adherence to disease-modifying therapies. Journal of Managed Care & Specialty Pharmacy 27:7, pages 915-923.
Crossref
Crossref
Thanh Phuong Pham Nguyen, Dina Jacobs, Dylan Thibault & Allison W. Willis. (2021) Multiple sclerosis hospitalizations among users of oral disease-modifying therapies. Multiple Sclerosis and Related Disorders 52, pages 102944.
Crossref
Crossref
J. Bradford Rice, Mary P. Panaccio, Alan White, Mark Simes, Emma Billmyer, Nathaniel Downes, John Niewoehner & George J. Wan. (2020) Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis. Neurology and Therapy 10:1, pages 149-167.
Crossref
Crossref
Jagadeswara R. Earla, George J. Hutton, Douglas J. Thornton, Hua Chen, Michael L. Johnson & Rajender R. Aparasu. (2021) Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:5, pages 440-450.
Crossref
Crossref
Joshua C. Toliver, Jamie C. Barner, Kenneth A. Lawson & Karen L. Rascati. (2021) Use of a claims-based algorithm to estimate disease severity in the multiple sclerosis Medicare population. Multiple Sclerosis and Related Disorders 49, pages 102741.
Crossref
Crossref
Maria Cecilia Vieira, Yunfeng Li, Xiangyi Meng, Huanxue Zhou, Olivia Wenxian Piao, Christen Kutz & Devon Conway. (2021) Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis–Related Relapses. International Journal of MS Care 23:2, pages 73-78.
Crossref
Crossref
Machaon Bonafede, Rina Mehta, Gilwan Kim, Ila Sruti, Marc Tian, Corey Pelletier & Neil Goldfarb. (2020) Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis. PharmacoEconomics - Open 5:1, pages 23-34.
Crossref
Crossref
Jacqueline Nicholas, Huanxue Zhou & Chinmay Deshpande. (2020) Annual Cost Burden by Level of Relapse Severity in Patients with Multiple Sclerosis. Advances in Therapy.
Crossref
Crossref
Joshua Toliver, Jamie C. Barner, Kenneth Lawson, Kalyani Sonawane & Karen Rascati. (2020) Replication of a Claims-based Algorithm to Estimate Multiple Sclerosis Disease Severity in a Commercially Insured Population. Multiple Sclerosis and Related Disorders 46, pages 102539.
Crossref
Crossref
Anaïs Lacasse, Elizabeth Cauvier Charest, Roxanne Dault, Anne-Marie Cloutier, Manon Choinière, Lucie Blais & Alain Vanasse. (2020) Validity of Algorithms for Identification of Individuals Suffering from Chronic Noncancer Pain in Administrative Databases: A Systematic Review. Pain Medicine 21:9, pages 1825-1839.
Crossref
Crossref
James Bowen, Rina Mehta, Corey Pelletier, Marc Tian, Virginia Noxon, Barbara H. Johnson & Machaon Bonafede. (2020) Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Advances in Therapy 37:7, pages 3163-3177.
Crossref
Crossref
Christoph Ohlmeier, Holger Gothe, Judith Haas, Ulrike Osowski, Carina Weinhold, Sarah Blauwitz, Niklas Schmedt, Wolfgang Galetzka, Fabian Berkemeier, Björn Tackenberg & Martin Stangel. (2020) Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. PLOS ONE 15:5, pages e0231846.
Crossref
Crossref
Tara Nazareth, Manasi Datar & Tzy-Chyi Yu. (2019) Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population. Neurology and Therapy 8:2, pages 383-395.
Crossref
Crossref
William J. Culpepper, Ruth Ann MarrieAnnette Langer-GouldMitchell T. WallinJonathan D. CampbellLorene M. NelsonWendy E. KayeLaurie WagnerHelen TremlettLie H. ChenStella LeungCharity EvansShenzhen YaoNicholas G. LaRoccaAlbert Lo, Robert McBurney, Oleg Muravov, Bari Talente & Leslie Ritter. (2019) Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology 92:10.
Crossref
Crossref
Edward Fox, Maria Cecilia Vieira, Kristen Johnson, Miranda Peeples, Arielle G. Bensimon, James Signorovitch & Vivian Herrera. (2019) Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis. Journal of the Neurological Sciences 398, pages 163-170.
Crossref
Crossref
Rishi J. DesaiMufaddal MahesriJoshua J. GagneEimir HurleyAngela TongTanuja ChitnisSarah MindenClaire M. SpettellOlga S. MatlinWilliam H. ShrankNiteesh K. Choudhry. (2019) Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 25:1, pages 113-121.
Crossref
Crossref
Sarah C MacDonald, Thomas F McElrath & Sonia Hernández-Díaz. (2019) Pregnancy Outcomes in Women With Multiple Sclerosis. American Journal of Epidemiology 188:1, pages 57-66.
Crossref
Crossref
Daniel Ontaneda, Jacqueline Nicholas, Matthew Carraro, Jia Zhou, Qiang Hou, Jaanai Babb, Katherine Riester, Jason P. Mendoza, Terrie Livingston & Mehul Jhaveri. (2019) Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Multiple Sclerosis and Related Disorders 27, pages 101-111.
Crossref
Crossref
Stanley Cohan, Kyle Smoot, Kiren Kresa-Reahl, Robert Garland, Wei-Shi Yeh, Ning Wu & Crystal Watson. (2018) Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study. Advances in Therapy 35:11, pages 1894-1904.
Crossref
Crossref
Maria K. HoutchensNatalie C. EdwardsAmy L. Phillips. (2018) Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology 91:17.
Crossref
Crossref
James D Bowen, Chris M Kozma, Megan M Grosso & Amy L Phillips. (2018) A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:4, pages 205521731881903.
Crossref
Crossref
Jay Visaria, Nina Thomas, Tao Gu, Joseph Singer & Hiangkiat Tan. (2018) Understanding the Patient's Journey in the Diagnosis and Treatment of Multiple Sclerosis in Clinical Practice. Clinical Therapeutics 40:6, pages 926-939.
Crossref
Crossref
Marti GroenewegSara H. ForresterBeth ArnoldLorella PalazzoWeiwei ZhuPaul YoonTim Scearce. (2018) One-Year Outcomes of an Integrated Multiple Sclerosis Disease Management Program. Journal of Managed Care & Specialty Pharmacy 24:5, pages 458-463.
Crossref
Crossref
Jacqueline Nicholas, Aaron Boster, Ning Wu, Wei-Shi Yeh, Monica Fay, Jon Kendter, Ming-Yi Huang & Andrew Lee. (2017) Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data. PharmacoEconomics - Open 2:1, pages 31-41.
Crossref
Crossref
Irene Eriksson, Thomas Cars, Fredrik Piehl, Rickard E. Malmström, Björn Wettermark & Mia von Euler. (2017) Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. European Journal of Clinical Pharmacology 74:2, pages 219-226.
Crossref
Crossref
James John Marriott, Hui Chen, Randall Fransoo & Ruth Ann Marrie. (2018) Validation of an algorithm to detect severe MS relapses in administrative health databases. Multiple Sclerosis and Related Disorders 19, pages 134-139.
Crossref
Crossref
Meritxell Sabidó-Espin & Rick Munschauer. (2017) Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study. BMC Neurology 17:1.
Crossref
Crossref
T. Ziemssen, D. Rothenbacher, J. Kuhle & T. Berger. (2017) Real-world-EvidenzReal-world evidence. Der Nervenarzt 88:10, pages 1153-1158.
Crossref
Crossref
Kristen M. JohnsonHuanxue ZhouFeng LinJohn J. KoVivian Herrera. (2017) Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year. Journal of Managed Care & Specialty Pharmacy 23:8, pages 844-852.
Crossref
Crossref
Aaron Boster, Jacqueline Nicholas, Ning Wu, Wei-Shi Yeh, Monica Fay, Michael Edwards, Ming-Yi Huang & Andrew Lee. (2017) Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurology and Therapy 6:1, pages 91-102.
Crossref
Crossref
Tjalf Ziemssen, Jennie Medin, C. Anne-Marie Couto & Catherine R. Mitchell. (2017) Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. Autoimmunity Reviews 16:4, pages 355-376.
Crossref
Crossref
Paola Colais, Nera Agabiti, Marina Davoli, Fabio Buttari, Diego Centonze, Chiara De Fino, Marta Di Folco, Graziella Filippini, Ada Francia, Simonetta Galgani, Claudio Gasperini, Manuela Giuliani, Massimiliano Mirabella, Viviana Nociti, Carlo Pozzilli & AnnaMaria Bargagli. (2017) Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy. Neuroepidemiology 48:3-4, pages 171-178.
Crossref
Crossref
Valery Risson, Bhaskar Ghodge, Ian C Bonzani, Jonathan R Korn, Jennie Medin, Tanmay Saraykar, Souvik Sengupta, Deepanshu Saini & Melvin Olson. (2016) Linked Patient-Reported Outcomes Data From Patients With Multiple Sclerosis Recruited on an Open Internet Platform to Health Care Claims Databases Identifies a Representative Population for Real-Life Data Analysis in Multiple Sclerosis. Journal of Medical Internet Research 18:9, pages e249.
Crossref
Crossref
Huanxue Zhou, Christopher Taber, Steve Arcona & Yunfeng Li. (2016) Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups. Applied Health Economics and Health Policy 14:4, pages 419-429.
Crossref
Crossref
Seoyoung C Kim, Sebastian Schneeweiss, Robert J Glynn, Michael Doherty, Allison B Goldfine & Daniel H Solomon. (2015) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Annals of the Rheumatic Diseases 74:11, pages 1968-1975.
Crossref
Crossref
Gorana Capkun, Frank Dahlke, Raquel Lahoz, Beth Nordstrom, Hugh H Tilson, Gary Cutter, Dorina Bischof, Alan Moore, Jason Simeone, Kathy Fraeman, Fabrice Bancken, Yvonne Geissbühler, Michael Wagner & Stanley Cohan. (2015) Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: An observational study using the US Department of Defense administrative claims database. Multiple Sclerosis and Related Disorders 4:6, pages 546-554.
Crossref
Crossref
Barbara H. Johnson, Machaon M. Bonafede & Crystal Watson. (2015) Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. CNS Drugs 29:6, pages 503-510.
Crossref
Crossref
Patricia K Coyle, Bruce A Cohen, Thomas Leist, Clyde Markowitz, MerriKay Oleen-Burkey, Marc Schwartz, Mark J Tullman & Howard Zwibel. (2014) Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurology 14:1.
Crossref
Crossref
Niklas Bergvall, Charles Makin, Raquel Lahoz, Neetu Agashivala, Ashish Pradhan, Gorana Capkun, Allison A. Petrilla, Swapna U. Karkare, Catherine Balderston McGuiness & Jonathan R. Korn. (2014) Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. PLoS ONE 9:2, pages e88472.
Crossref
Crossref
Karina Raimundo, Haijun Tian, Huanxue Zhou, Xin Zhang, Kristijan H Kahler, Neetu Agashivala & Edward Kim. (2013) Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Services Research 13:1.
Crossref
Crossref
Hélène Parisé, François Laliberté, Patrick Lefebvre, Mei Sheng Duh, Edward Kim, Neetu Agashivala, Safiya Abouzaid & Bianca Weinstock-Guttman. (2013) Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers. Journal of the Neurological Sciences 330:1-2, pages 71-77.
Crossref
Crossref
DE Furst, A Clarke, AW Fernandes, T Bancroft, K Gajria, W Greth & SR Iorga. (2013) Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Lupus 22:3, pages 268-278.
Crossref
Crossref
DANIEL E. FURST, ANCILLA W. FERNANDES, SERBAN R. IORGA, WARREN GRETH & TIM BANCROFT. (2012) Annual Medical Costs and Healthcare Resource Use in Patients with Systemic Sclerosis in an Insured Population. The Journal of Rheumatology 39:12, pages 2303-2309.
Crossref
Crossref
Daniel E. Furst, Anthony A. Amato, Şerban R. Iorga, Tim Bancroft & Ancilla W. Fernandes. (2012) Medical costs and health-care resource use in patients with inflammatory myopathies in an insured population. Muscle & Nerve 46:4, pages 496-505.
Crossref
Crossref
Daniel E. Furst, Anthony A. Amato, Şerban R. Iorga, Kavita Gajria & Ancilla W. Fernandes. (2012) Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle & Nerve 45:5, pages 676-683.
Crossref
Crossref
Rachel Halpern, Sonalee Agarwal, Leigh Borton, Kathy Oneacre & Maria V. Lopez-Bresnahan. (2011) Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: Retrospective claims analysis. Advances in Therapy 28:9, pages 761-775.
Crossref
Crossref